Empowered Funds LLC Buys 267,686 Shares of Roivant Sciences Ltd. $ROIV

Key Points

• Empowered Funds LLC increased its Roivant Sciences stake by 1,468.5% in the first quarter, purchasing 267,686 shares and bringing its holdings to 285,915 shares valued at approximately $7.92 million. Institutional investors collectively own 64.76% of the company.
• Roivant insiders sold 2.06 million shares worth about $69.6 million over the past three months, including Director Daniel Allen Gold’s sale of 800,000 shares for $27.64 million.
• ROIV opened at $36.20, near its 52-week high of $37.00. Analysts maintain a “Moderate Buy” consensus with an average price target of $35.14, although Citigroup recently raised its target to $46.00.

Empowered Funds LLC boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1,468.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 285,915 shares of the company's stock after purchasing an additional 267,686 shares during the period. Empowered Funds LLC's holdings in Roivant Sciences were worth $7,920,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Allworth Financial LP increased its holdings in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after acquiring an additional 583 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after purchasing an additional 1,166 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Roivant Sciences in the fourth quarter worth $47,000. Parallel Advisors LLC increased its stake in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in shares of Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock valued at $59,000 after purchasing an additional 2,665 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of the firm's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the completion of the transaction, the director owned 16,474 shares in the company, valued at $566,376.12. This trade represents a 51.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the sale, the director directly owned 13,701,546 shares in the company, valued at approximately $473,388,414.30. The trade was a 5.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 2,055,913 shares of company stock valued at $69,639,633. Insiders own 8.80% of the company's stock.

Roivant Sciences Stock Down 0.2%

ROIV opened at $36.20 on Friday. The company has a market capitalization of $26.04 billion, a PE ratio of -68.30 and a beta of 1.12. The firm has a 50-day simple moving average of $33.84 and a two-hundred day simple moving average of $29.91. Roivant Sciences Ltd. has a 52 week low of $11.54 and a 52 week high of $37.00.

Analysts Set New Price Targets

Several brokerages recently weighed in on ROIV. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a report on Thursday, August 6th. Sanford C. Bernstein upgraded Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. Citigroup upped their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Finally, Weiss Ratings cut Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $35.14.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source